%0 Journal Article
%T Sinonasal Inverted Papilloma-Associated and De Novo Squamous Cell Carcinoma: A Tale of Two Cities or Not.
%A Wang Z
%A Zhang Y
%A Zhang J
%A Chen X
%A Wang J
%A Wu R
%A Wang K
%A Qu Y
%A Huang X
%A Luo J
%A Gao L
%A Xu G
%A Liu S
%A Li YX
%A Yi J
%J Cancers (Basel)
%V 14
%N 21
%D Oct 2022 24
%M 36358630
%F 6.575
%R 10.3390/cancers14215211
%X <B>BACKGROUND: </B>Sinonasal squamous cell carcinoma (SNSCC) can arise as either inverted papilloma-associated SCC (IP-SCC) or as de novo SCC (DN-SCC). It is controversial as to whether survival differences between IP-SCC and DN-SCC exist.<BR><B>METHODS: </B>Between January 2000 and December 2016, 234 patients with SNSCC were analyzed retrospectively, including 68 with IP-SCC and 166 with DN-SCC. Propensity score matching (PSM) was performed to balance baseline characteristics. The Kaplan-Meier method and Cox proportional hazard model were used to determine risk factors on survival outcomes.<BR><B>RESULTS: </B>The median follow-up time was 98.4 months. Before PSM, lymph node metastasis was noted to be lower in patients with IP-SCC. After PSM, the 5-year DFS, DSS and OS between IP-SCC and DN-SCC were 43.0% vs. 44.5% (p = 0.701), 49.2% vs. 56.2% (p = 0.753), and 48.2% vs. 52.9% (p = 0.978). The annual hazards of local failure, respectively, peaked at 28.4% and 27.8% for IP-SCC and DN-SCC within 12 months after treatment. Afterward, the hazards gradually decreased and the hazard for IP-SCC was always higher before approaching null.<BR><B>CONCLUSIONS: </B>This study provides novel evidence to support the clinical utility of improved distinction between IP-SCC and DN-SCC. Further studies are necessary to validate these findings before considering escalation of IP-SCC.